LONDON (Reuters) - AstraZeneca on Wednesday said it was working with European and British regulators to change the product information on its COVID-19 shot after authorities said they suspected possible brain blood clots were a rare side-effect of the shot.
"Both of these reviews reaffirmed the vaccine offers a high-level of protection against all severities of COVID-19 and that these benefits continue to far outweigh the risks," AstraZeneca said in a statement.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!